Arthur Kuan, a distinguished Forbes 30 Under 30 honoree, is the current CEO and Director of the California-based biopharma company, CG Oncology. Focused on the development of a genetically modified virus, Kuan has spearheaded the fight against bladder cancer and other tumors that have previously been difficult to treat. Prior to his success at CG Oncology, Kuan served as a Founding Member of Ally Bridge Group, an analyst at Themes Investment Management Ltd., and DNV Capital 德诺资本. He has also notably been a committee member of the IP Commercialization Strategy for the prestigious Moffitt Cancer Center. Kuan's education background includes obtaining a Master of Science in Biotechnology from The Johns Hopkins University and a Bachelor of Arts degree in Molecular Biology from the University of Pennsylvania. His passion for biotech and dedication to fighting cancer has made him a prominent figure in the field.